BRAF and cancer: Thyroid-stimulating hormone levels are closely associated with PTC recurrence, metastasis, and cancer-related death, especially in high-risk PTC patients.[9] In addition, Huy Gia Vuong[10] published a meta-analysis on the prognosis of PTC patients with BRAF and TERT promoter mutations in clinical endocrinology in March 2017.